Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shiowjen Lee

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Statistics in Medicine|November 22, 2016
Validity and power considerations on hypothesis testing under minimizationZhenzhen Xu, Michael Proschan, Shiowjen Lee
Journal of Biopharmaceutical Statistics|February 26, 2010
Missing data handling methods in medical device clinical trialsXu Yan, Shiowjen Lee, Ning Li
Statistics in Medicine|January 21, 2016
Validity and power considerations on hypothesis testing under minimizationZhenzhen Xu, Michael Proschan, Shiowjen Lee
JAMA Oncology|May 1, 2020
Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With CancerTao Wang, Shiowjen Lee, Gerald M Feldman
Therapeutic Innovation & Regulatory Science|September 21, 2020
Graphical Analyses in the Regulatory Evaluation of Gene Therapy ApplicationsXue Lin, Shiowjen Lee, John Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2022
Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical PerspectiveXue Lin, Shiowjen Lee, Poornima Sharma, et al.
Journal of Biopharmaceutical Statistics|March 17, 2007
Mixed noninferiority margin and statistical tests in active controlled trialsHsiao-Hui Tsou, Chin-Fu Hsiao, Shein-Chung Chow, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
CBER's Experience With Adaptive Design Clinical TrialsMin Lin, Shiowjen Lee, Boguang Zhen, et al.
Oncoimmunology|December 15, 2018
BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathwaysPeng Yue, Taylor Harper, Silvia M Bacot, et al.
International Journal of Molecular Sciences|December 2, 2020
Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 ImmunotherapySilvia M Bacot, Taylor A Harper, Rebecca L Matthews, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|November 22, 2016
Validity and power considerations on hypothesis testing under minimizationZhenzhen Xu, Michael Proschan, Shiowjen Lee
Journal of Biopharmaceutical Statistics|February 26, 2010
Missing data handling methods in medical device clinical trialsXu Yan, Shiowjen Lee, Ning Li
Statistics in Medicine|January 21, 2016
Validity and power considerations on hypothesis testing under minimizationZhenzhen Xu, Michael Proschan, Shiowjen Lee
JAMA Oncology|May 1, 2020
Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With CancerTao Wang, Shiowjen Lee, Gerald M Feldman
Therapeutic Innovation & Regulatory Science|September 21, 2020
Graphical Analyses in the Regulatory Evaluation of Gene Therapy ApplicationsXue Lin, Shiowjen Lee, John Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2022
Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical PerspectiveXue Lin, Shiowjen Lee, Poornima Sharma, et al.
Journal of Biopharmaceutical Statistics|March 17, 2007
Mixed noninferiority margin and statistical tests in active controlled trialsHsiao-Hui Tsou, Chin-Fu Hsiao, Shein-Chung Chow, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
CBER's Experience With Adaptive Design Clinical TrialsMin Lin, Shiowjen Lee, Boguang Zhen, et al.
Oncoimmunology|December 15, 2018
BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathwaysPeng Yue, Taylor Harper, Silvia M Bacot, et al.
International Journal of Molecular Sciences|December 2, 2020
Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 ImmunotherapySilvia M Bacot, Taylor A Harper, Rebecca L Matthews, et al.
Pageof 2